Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.
For more than six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Newsletters
Bylined Articles
Leading Matters
Client Highlights
Wilson Sonsini Advises Obsidio on Its Acquisition by Boston Scientific
On August 15, 2022, Boston Scientific Corporation announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM) technology used for embolization of blood vessels in the peripheral vasculature. Specific terms of the transaction have not been disclosed.
Client Highlights
Wilson Sonsini Advises AliveCor in Series F Financing
On August 16, 2022, AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, announced its Series F Financing led by GE Healthcare. Also joining the round are NGK-NTK (through a CVC partnership with Pegasus Tech Ventures) and existing investors including Khosla Ventures, Bold Capital Partners, Qualcomm Ventures, and WP Global Partners. Wilson Sonsini Goodrich & Rosati advised AliveCor in the financing.
AliveCor will use this financing to advance its mission of becoming a premier provider of end-to-end cardiological care for patients when they are not in front of their cardiologists by introducing subscription services, KardiaCare and KardiaComplete for patients, payers and employers, and KardiaPro for physicians. These subscription services are supported by the company's personal ECG devices, including KardiaMobile, KardiaMobile 6L, and KardiaMobile Card. This financing will also allow for continued advancements in AliveCor's AI roadmap and pipeline of innovations.
AliveCor will use this financing to advance its mission of becoming a premier provider of end-to-end cardiological care for patients when they are not in front of their cardiologists by introducing subscription services, KardiaCare and KardiaComplete for patients, payers and employers, and KardiaPro for physicians. These subscription services are supported by the company's personal ECG devices, including KardiaMobile, KardiaMobile 6L, and KardiaMobile Card. This financing will also allow for continued advancements in AliveCor's AI roadmap and pipeline of innovations.
Client Highlights
Wilson Sonsini Advises Lumentum on Acquisition of IPG Photonics’ Telecom Transmission Product Lines
On August 15, 2022, Lumentum Holdings Inc. announced that it has acquired IPG Photonics' telecom transmission product lines in an all-cash transaction. According to the press release, the acquisition adds "highly complementary and differentiated transceiver product lines and ASIC capabilities" to Lumentum, which will "help expand [the] addressable market and augment [Lumentum's] technology capabilities.” Terms of the transaction were not disclosed.
Client Highlights
Wilson Sonsini Advises BigHat Biosciences on IP and Licensing Matters Related to $75 Million Series B
On July 20, 2022, BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, announced the completion of a Series B financing of $75 million led by Section 32, with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, and GRIDS Capital. Prior investors Andreessen Horowitz, 8VC, and AME Cloud Ventures also contributed to this round. The company has raised over $100 million to date. Wilson Sonsini Goodrich & Rosati provides support in IP and licensing matters to BigHat Biosciences.
Client Highlights
Wilson Sonsini Advises Marengo Therapeutics on Patent Matters Related to Strategic Partnership with Ipsen
On August 1, 2022, Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s proprietary R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint for clinical development and commercialization. Under the terms of the agreement, Ipsen will make an upfront payment of $45 million, together with potential payments up to a total of $1.592 billion if all milestones are met in addition to tiered sales royalty payments. Marengo will lead the preclinical development efforts and will expense related costs until the submission of an Investigational New Drug (IND) application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization.
Client Highlights
Wilson Sonsini Advises MiroBio on Patent Matters Related to Acquisition by Gilead
On August 4, 2022, Gilead Sciences and MiroBio, a privately-held UK-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed earlier this week. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response.
The Entrepreneurs Report – 1H 2022
In this latest issue of The Entrepreneurs Report, we've compiled a range of data on venture financing transactions in which the firm was involved during the first half of 2022, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general. This edition also includes data from Beauhurst—a searchable database of the UK's high-growth companies—on UK equity investment in 1H 2022.